New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:54 EDTLH, MYGNMyriad remains in Horizon New Jersey network, says William Blair
William Blair believes there is confusion around Horizon BCBS of New Jersey's BRCA commentary, which it feels attributed to the recent pullback in shares of Myriad Genetics (MYGN). The firm said Horizon reiterated LabCorp's (LH) preferred network status and suggested that doctors should use LabCorp for BRCA testing. The insurer does not refer to a change in Myriadís network status as a participating provider in Horizonís network, the firm points out. William Blair says it has not seen evidence that Myriad is being excluded as a network provider. It maintains an Outperform rating on the stock.
News For MYGN;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
12:12 EDTMYGNMyriad Genetics receives FDA approval of BRACAnalysis CDx
Myriad Genetics (MYGN) announced that it has received approval from the U.S. FDA for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's (AZN) drug Lynparza. Lynparza is the first poly ADP-ribose polymerase inhibitor for patients with germline mutations in BRCA1/2 advanced ovarian cancer who have had three or more lines of chemotherapy. BRACAnalysis CDx is Myriad's first FDA-approved companion diagnostic for use with a novel PARP inhibitor. BRACAnalysis CDx is a highly accurate molecular companion diagnostic test that identifies deleterious or suspected deleterious mutations in the BRCA1 and BRCA2 genes, using DNA obtained from a blood sample. BRACAnalysis CDx was proven in clinical studies to effectively identify patients with BRCA mutations who would be candidates for Lynparza. The approval of BRACAnalysis CDx demonstrates Myriad's commitment to developing companion diagnostics and is the culmination of an intensive, multiyear scientific collaboration with AstraZeneca to advance personalized medicine for women with ovarian cancer.
10:17 EDTMYGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:15 EDTMYGNMyriad Genetics initiated with a Market Perform at Wells Fargo
Subscribe for More Information
December 18, 2014
09:07 EDTLHLabCorp announces availability of test to identify enterovirus D-68
LabCorp announced the availability of a reflex test to identify enterovirus D68, which is associated with severe respiratory illness that primarily affects children. The EV-D68 PCR test determines the presence or absence of enteroviral RNA in a respiratory sample, and if positive, reflexes to an EV-D68-specific PCR test. The EV-D68 subtyping PCR test enables the presence or absence of the predominant D68 strain to be determined.
December 17, 2014
10:21 EDTMYGNMyriad denied appeal to block competing breast cancer tests, Bloombeg reports
Subscribe for More Information
December 16, 2014
08:46 EDTLHLabCorp, Covance announce expiration of Hart-Scott-Rodino waiting period
Subscribe for More Information
December 15, 2014
10:10 EDTLHHigh option volume stocks:
High option volume stocks: RVBD AGCO FRO CRUS UBNT LH PAY PETM OREX KOS
December 11, 2014
12:54 EDTMYGNMyriad Genetics management to meet with William Blair
Subscribe for More Information
December 9, 2014
15:31 EDTLHLabCorp management to meet with Craig-Hallum
Meeting to be held in Baltimore on December 10 hosted by Craig-Hallum.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use